Acutaas Chemicals (ACUTAAS) Q1 25/26 earnings summary

Executive summary

• Q1 FY26 revenue grew 17.3% year-over-year to INR 2,072 million, led by advanced pharmaceutical intermediates and supported by PMDA GMP certification of both pharma facilities.

• Strong momentum in battery chemicals and semiconductor segments, with new product introductions and a major joint venture in South Korea (Indichem) for specialty chip chemicals.

• Customer engagement increased across CDMO, battery chemicals, and semiconductors, setting a positive tone for FY26.

• Unaudited standalone and consolidated financial results for the quarter ended June 30, 2025, were approved by the Board and reviewed by statutory auditors with no modifications.

• The company operates in a single segment: custom synthesis and manufacturing of specialty chemicals for pharmaceuticals and related applications.

Financial highlights

• Q1 FY26 consolidated revenue from operations was ₹20,723.72 lakhs, up from ₹17,667.09 lakhs in Q1 FY25; EBITDA stood at ₹509 million, up 72.4% YoY.

• Gross margin improved to 53.2% from 42.1% in Q1 FY25; EBITDA margin rose to 24.6% from 16.7%.

• Consolidated profit for the period was ₹4,401.05 lakhs, compared to ₹1,468.97 lakhs in Q1 FY25; PAT up 199.6%.

• Net cash and cash equivalents at INR 270 crore; operating cash flow of INR 94.6 crore generated in the quarter.

• Basic and diluted EPS (consolidated) for Q1 FY26 was ₹5.41, up from ₹1.83 in Q1 FY25.

Outlook and guidance

• Management reaffirmed 25% revenue growth guidance for FY26, with sequential improvement and stronger margins expected.

• Margin improvement expected, with gross margins anticipated to remain above 50% due to sustainable cost measures and favorable product mix.

• Commercialization of new CDMO projects and electrolyte additives expected to contribute from Q4 FY26.

• The company continues to focus on capital expenditure for electrolyte additives and allied businesses, with significant investments planned in its subsidiaries.